NCT03631862

Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

A Randomized Controlled Clinical Trial of Apatinib Combined With CHOP Regimen in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Zhengzhou University · Academic / Other
• Sex: All
• Age: 14 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of Apatinib Combined With CHOP Regimen(cyclophosphamide, vincristine, epirubicin, prednisone in the treatment of newly diagnosed peripheral T-cell lymphoma.

Detailed description

Patients with peripheral T-cell lymphoma usually have a bad prognosis. These patients cannot be treated successfully with the conventional CHOP regimen. Apatinib is a small-molecule multitargeted tyrosine kinase inhibitor. The investigators have been proceeding this trial to evaluate the efficacy and safety of the Apatinib Combined With CHOP Regimen(cyclophosphamide, vincristine, epirubicin, prednisone in the treatment of newly diagnosed peripheral T-cell lymphoma.

Conditions

• Newly Diagnosed Peripheral T-cell Lymphoma

Interventions

Type	Name	Description
DRUG	Apatinib	Apatinib is an orally administrated small molecule receptor tyrosine kinase inhibitor selectively targeting VEGFR-2, showing anti-tumor activity across a broad range of advanced cancers.
DRUG	CHOP Regimen	CHOP regimen(Cyclophosphamide,Vindesine,Epirubicin,Prednisone)

Timeline

• Start date: 2018-09-01
• Primary completion: 2019-12-31
• Completion: 2019-12-31
• First posted: 2018-08-15
• Last updated: 2018-08-15

Locations

1 site across 1 country: China